IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Sunesis Pharmaceuticals, Inc. (“Sunesis” or the “Company”) (Nasdaq: SNSS) concerning possible violations of federal securities laws.
If you purchased shares of Sunesis and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
The investigation focuses on whether Sunesis and certain of its officers and/or directors violated federal securities laws. On May 2, 2017, Sunesis announced that it will withdraw its European Marketing Authorization Application for vosaroxin, its proposed treatment for relapsed/refractory AML. Sunesis stated that its decision followed recent interactions with the European Medicine Agency’s Committee for Medicinal Products for Human Use, in which it learned that the committee was likely to adopt a negative opinion in its evaluation of the product.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.